303 related articles for article (PubMed ID: 24714565)
1. Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination.
Verkoczy L; Diaz M
Curr Opin HIV AIDS; 2014 May; 9(3):224-34. PubMed ID: 24714565
[TBL] [Abstract][Full Text] [Related]
2. Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.
Verkoczy L; Alt FW; Tian M
Immunol Rev; 2017 Jan; 275(1):89-107. PubMed ID: 28133799
[TBL] [Abstract][Full Text] [Related]
3. Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.
Verkoczy L
Adv Immunol; 2017; 134():235-352. PubMed ID: 28413022
[TBL] [Abstract][Full Text] [Related]
4. Poly- and autoreactivity of HIV-1 bNAbs: implications for vaccine design.
Finney J; Kelsoe G
Retrovirology; 2018 Jul; 15(1):53. PubMed ID: 30055635
[TBL] [Abstract][Full Text] [Related]
5. Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?
Subbaraman H; Schanz M; Trkola A
Retrovirology; 2018 Jul; 15(1):52. PubMed ID: 30055627
[TBL] [Abstract][Full Text] [Related]
6. Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies.
Mabvakure BM; Scheepers C; Garrett N; Abdool Karim S; Williamson C; Morris L; Moore PL
J Virol; 2019 Mar; 93(6):. PubMed ID: 30567996
[TBL] [Abstract][Full Text] [Related]
7. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
[TBL] [Abstract][Full Text] [Related]
8. Correlates of broadly neutralizing antibody development.
Abela IA; Kadelka C; Trkola A
Curr Opin HIV AIDS; 2019 Jul; 14(4):279-285. PubMed ID: 31107283
[TBL] [Abstract][Full Text] [Related]
9. Host controls of HIV broadly neutralizing antibody development.
Kelsoe G; Haynes BF
Immunol Rev; 2017 Jan; 275(1):79-88. PubMed ID: 28133807
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes.
Ditse Z; Muenchhoff M; Adland E; Jooste P; Goulder P; Moore PL; Morris L
J Virol; 2018 Sep; 92(17):. PubMed ID: 29950423
[TBL] [Abstract][Full Text] [Related]
11. Targeting broadly neutralizing antibody precursors: a naïve approach to vaccine design.
McGuire AT
Curr Opin HIV AIDS; 2019 Jul; 14(4):294-301. PubMed ID: 30946041
[TBL] [Abstract][Full Text] [Related]
12. Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies.
Ahmed Y; Tian M; Gao Y
AIDS Res Ther; 2017 Sep; 14(1):50. PubMed ID: 28893278
[TBL] [Abstract][Full Text] [Related]
13. Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: selection against membrane proximal external region-associated autoreactivity limits T-dependent responses.
Verkoczy L; Chen Y; Zhang J; Bouton-Verville H; Newman A; Lockwood B; Scearce RM; Montefiori DC; Dennison SM; Xia SM; Hwang KK; Liao HX; Alam SM; Haynes BF
J Immunol; 2013 Sep; 191(5):2538-50. PubMed ID: 23918977
[TBL] [Abstract][Full Text] [Related]
14. Progress in HIV vaccine development.
Hsu DC; O'Connell RJ
Hum Vaccin Immunother; 2017 May; 13(5):1018-1030. PubMed ID: 28281871
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen.
Jardine JG; Ota T; Sok D; Pauthner M; Kulp DW; Kalyuzhniy O; Skog PD; Thinnes TC; Bhullar D; Briney B; Menis S; Jones M; Kubitz M; Spencer S; Adachi Y; Burton DR; Schief WR; Nemazee D
Science; 2015 Jul; 349(6244):156-61. PubMed ID: 26089355
[TBL] [Abstract][Full Text] [Related]
16. Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection.
Derdeyn CA; Moore PL; Morris L
Curr Opin HIV AIDS; 2014 May; 9(3):210-6. PubMed ID: 24662931
[TBL] [Abstract][Full Text] [Related]
17. Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies.
Verkoczy L; Kelsoe G; Moody MA; Haynes BF
Curr Opin Immunol; 2011 Jun; 23(3):383-90. PubMed ID: 21524897
[TBL] [Abstract][Full Text] [Related]
18. Immunological mechanisms of inducing HIV immunity in infants.
Fouda GG; De Paris K; Levy O; Marchant A; Gray G; Permar S; Marovich M; Singh A
Vaccine; 2020 Jan; 38(3):411-415. PubMed ID: 31761501
[TBL] [Abstract][Full Text] [Related]
19. Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages.
Zhang R; Verkoczy L; Wiehe K; Munir Alam S; Nicely NI; Santra S; Bradley T; Pemble CW; Zhang J; Gao F; Montefiori DC; Bouton-Verville H; Kelsoe G; Larimore K; Greenberg PD; Parks R; Foulger A; Peel JN; Luo K; Lu X; Trama AM; Vandergrift N; Tomaras GD; Kepler TB; Moody MA; Liao HX; Haynes BF
Sci Transl Med; 2016 Apr; 8(336):336ra62. PubMed ID: 27122615
[TBL] [Abstract][Full Text] [Related]
20. Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10.
Chen Y; Zhang J; Hwang KK; Bouton-Verville H; Xia SM; Newman A; Ouyang YB; Haynes BF; Verkoczy L
J Immunol; 2013 Aug; 191(3):1260-75. PubMed ID: 23825311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]